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Abstract
Spirulina is a microscopic and filamentous cyanobacterium that contains essential amino acids, essential fatty acids, vitamins, minerals and anti-oxidative
components. The purpose of this study was to examine effects of spirulina intervention in Korean patients with type 2 diabetes. The subjects were
37 type 2 diabetic patients who visited a diabetic clinic in Seoul and randomly assigned into spirulina (8 g/day) or control group. During the intervention
period of 12 weeks, subjects were asked to keep usual diet and prohibited to take any functional foods or dietary supplements. Spirulina supplementation 
for 12 weeks did not affect anthropometric parameters, however, lowered plasma triglycerides level significantly (p<0.05). Spirulina supplementation
also resulted in a significant reduction in plasma malondialdehyde level (p<0.05) and an increase in plasma adiponectin level (p<0.1). The lipid 
lowering effect of spirulina supplementation was different according to serum lipid levels of the subjects before entering the intervention. The subjects
with higher initial triglyceride level showed higher reduction in plasma triglyceride and blood pressure. The subjects with higher initial total cholesterol
and LDL-cholesterol level showed higher reduction in plasma concentrations of total cholesterol, LDL-cholesterol, IL-6, and blood pressure. It seems
that spirulina supplementation is more effective in subjects with dyslipidemia. This study provides the evidence for beneficial effects of spirulina
supplementation on blood lipid profiles, inflammatory variables, and antioxidant capacity in Korean patients with type 2 diabetes. The results suggest
that spirulina is a promising agent as a functional food for diabetes management.
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The prevalence of diabetes mellitus has been rapidly increasing 
in Korea. Diet plays a key role in the treatment of diabetes and 
proper nutrition is vital to prevent diabetes complications (Park 
& Ahn, 2007). However, it is not an easy task to follow diabetic diet 
prescription and the compliance with diabetic diet recommendations 
is reported to be very poor (Woo et al., 2006). In recent years, 
functional foods have appeared as new means to help maintain 
proper nutrition in patients with chronic diseases such as diabetes.
Spirulina (arthrospira platensis) has received much attention 
as functional food regarding its association with cholesterol- 
regulatory properties, modulation of the host immune system, 
and antioxidant capacity (Hirata et al., 2000; Qureshi et al., 
1995). There is increasing scientific and clinical evidences for 
its role in controlling chronic diseases such as diabetes (Iyer et 
al., 2001), arthritis (Mishra et al., 1998), anemia (Iyer et al., 
2000) and cancer (Mathew et al., 1995). 
Spirulina is a microscopic and filamentous cyanobacterium 
(blue-green alga) that has a long history of use as a food for 
humans. Spirulina is a rich source of protein and vitamins, 
especially vitamin B12, minerals, carotenoids, and phycocyanins. 
Its safety as food has been established through toxicological study
 
(Salazar  et al., 1996).
Over the past decade, numerous studies have been conducted 
to evaluate the effect of spirulina supplementation on promoting 
health and controlling various disorders in humans (Kim & Kim, 
2005; Parikh et al., 2001; Rodriguez-Hernandez et al., 2001). 
Blood lipid lowering effect of spirulina has been reported in 
healthy subjects (Park & Kim, 2003), patients with heart disease 
(Ramamoorthy & Premakumari, 1996), and diabetic patients 
(Mani  et al., 2000). Antioxidant properties of spirulina were 
demonstrated in a report on the inhibition of lipid peroxidation 
by its extract (Benedetti et al., 2004), and immuno-enhancing 
effect was seen in mice fed spirulina-containing diet (Hayashi 
et al., 1994).
We have also reported that spirulina supplementation to healthy 
elderly people resulted in significant reductions of plasma 
triglycerides, total-and LDL-cholesterol, blood pressure, and 
improving the antioxidant status, as well as inflammatory status 
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and came to conclusion that it was suitable as a functional food 
for elderly people (Park & Kim, 2003; Park et al., 2008). 
However, the effect of spirulina as a functional food for patients 
with diabetes has not been evaluated. In this study, we aimed 
to evaluate the effectiveness of spirulina as functional food in 
Korean patients with type 2 diabetes. 
Subjects and Methods
Subjects and experimental protocol 
The study subjects were recruited from a diabetes clinic in 
Seoul from September 2007 to May 2008. Current users of 
medications for diabetes, dyslipidemia, and inflammatory diseases 
and of vitamin supplements were excluded. Finally 37 subjects 
(20 male, 17 female) were enrolled in this study. The research 
protocol was approved by ‘Institutional Review Board (IRB)’ 
of Yonsei University. All subjects gave written informed consent 
before beginning the study.
At the first visit for intervention study, blood was drawn after 
a minimum of 12 h of fasting. Anthropometric and biochemical 
parameters and nutrient intakes were measured for baseline data. 
The enrolled subjects were randomly assigned into either 
spirulina or control group. When the subject entered the trial, 
the subject chose a numbered sealed envelope containing the 
randomized allocation to the spirulina (intervention) or control 
(no intervention) group. 
The subjects in spirulina group received 40 pills containing 
0.2 g of freeze-dried spirulina (8.0 g/day) for 12 consecutive 
weeks and control group was instructed not to take any functional 
foods or supplements. During the intervention period, both 
spirulina and control groups were asked to maintain their usual 
diets and levels of physical activity. They were also required 
to abstain from taking any other supplements. 
The compliance for all subjects was confirmed by telephone 
twice a week. Anthropometric and biochemical parameters were 
measured before and after the intervention period for both 
spirulina and control groups. The spirulina was provided by Earth 
Spirulina Group (ES Co, Seoul, Korea) and sent to subjects every 
2 weeks. 
Anthropometric, hematological and dietary assessment
The subjects were individually interviewed to obtain general 
characteristics, life-style behavior and food consumption. Body 
weight, height and body composition were measured using 
In-body 4.0 (Biospace Co. Korea) and body mass index (BMI, 
kg/m
2) was calculated. Waist circumference was measured by 
a tapeline and abdominal fat thickness was assessed by 
ultrasonographic measurement (General Electric logic 7. USA). 
The systolic and diastolic blood pressures were measured twice 
using an automatic blood pressure calculator (Biospace Co. 
Korea) after 10 minute rest. 
The daily nutrient intakes were assessed using Food Frequency 
Questionnaire (FFQ). Dietary intakes data were analyzed by 
Can-pro 2.0 software (The Korean Nutrition Society, Korea).
Serum levels of glucose, triglyceride, total-cholesterol, and HDL- 
cholesterol were measured using an autoanalyzer (COBAS MIRA. 
Roche. Switzerland). LDL-cholesterol and atherogenic index (AI) 
were calculated as described by Friendewald et al. (1972)
  and 
Lauer  et al., (1998), respectively [LDL-cholesterol=Total 
cholesterol-HDL-cholesterol-(Triglyceride / 5), Atherogenic index 
(AI)=(Total cholesterol-HDL-cholesterol / HDL-cholesterol)]. The 
analysis of insulin was performed at ‘Seoul Medical Science 
Institute (SCL)’ and Hemoglobin A1c was measured using an 
analyzer (HLC-723 G7, Tosoh, Japan). 
The KITT value (%/min, insulin tolerance test) was used to 
assess insulin resistance. Insulin (Humulin
®, RI 0.11 U/kg body 
weight) was given intravenously after a 12 h fast. Plasma glucose 
was then measured at 0, 3, 6, 9, 12, and 15 min. After the plasma 
glucose levels were converted to natural logarithms, the slope 
of the reduction in plasma glucose (KITT) was calculated: KITT 
= 0.693/t1/2×100 (%/min) (Monzillo & Hamdy, 2003).
Inflammation and antioxidant status assessment 
Serum adiponectin concentration was determined with enzyme 
linked immunosorbent assay (ELlSA) kits (Mesdia Technology 
Inc., Korea) according to the manufacturer’s instructions. Ten 
microliters of serum samples were assayed in parallel to known 
adiponectin recombinant concentrations. Each assay was calibrated 
using an adiponectin standard curve.
Serum IL-6 and TNF-α concentrations were determined by enzyme 
linked immunosorbent assay (ELlSA) technique (Quantikine, R&D 
Systems Inc., USA) reading ELISA reader (Spectra Max 340, USA). 
Serum malondialdehyde (MDA) level, an index of antioxidant 
capacity, was measured using a Lipid Peroxidation Assay kit 
(Oxford Biomedical Research, USA). This assay is based on the 
reaction of a chromogenic reagent, N-methyl-2-phenylindole 
(R1), with MDA at 45℃. The reactive product produces a 
chromopore that has a stable violet color, the intensity of which 
is measured at 586 nm. MDA concentration was calculated using 
a MDA standard curve. 
Statistical analysis
Statistical analysis was performed with the SPSS program 
(version 12.0). Data were presented as mean ± S.E. Chi-square 
test was performed to determine differences at baseline in 
frequencies of categorized variables between the groups and 
mean differences were analyzed by analysis of covariance 
(ANCOVA). Paired t-test was used to analyze mean differences 
for all measured parameters between baseline and end of 
intervention period. To demonstrate the association between 
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Table 1. Baseline characteristics of subjects in the intervention study
Variables Spirulina (n=19) Control (n=18)
Age (years) 52.1 ± 2.3
1) 54.5 ± 1.5
Sex (Male/Female, %) 47.4/52.6 61.1/38.9 
Duration of DM (years) 2.8 ± 4.6 2.1 ± 4.9
Cigarette smoking (yes, %) 10.5 29.4
Alcohol drinking (yes, %) 36.8 38.9
Anthropometric variables
Weight (kg) 62.7 ± 2.2 64.9 ± 2.7
BMI (kg/m
2) 23.8 ± 0.5 23.4 ± 0.5
WHR 0.90 ± 0.01  0.90 ± 0.01
Diet intakes
Energy (kcal/day) 1806.5 ± 111.7 1808.9 ± 114.8
Protein (g/day) 74.7 ± 5.8 79.4 ± 6.0
Fat (g/day) 46.4 ± 4.6 49.1 ± 4.7
Carbohydrate (g/day) 267.2 ± 14.5 253.7 ± 14.9
Biochemical variables
Fasting blood glucose (mg/dl) 128.0 ± 3.8 127.8 ± 3.5
Insulin (ng/dl) 10.7 ± 0.7  9.7 ± 0.9
Total-cholesterol (mg/dl) 203.1 ± 8.1 186.9 ± 6.4
LDL-cholesterol (mg/dl) 129.4 ± 7.5 106.9 ± 6.5
HDL-cholesterol (mg/dl) 48.8 ± 3.0 52.6 ± 3.2
Triglyceride (mg/dl) 125.8 ± 14.1 110.7 ± 14.1
KITT index  2.67 ± 0.16  2.61 ± 0.20
Blood pressure
SBP (mmHg) 130.7 ± 3.8 131.8 ± 4.0
DBP (mmHg) 84.0 ± 2.1 80.1 ± 2.5
1) Mean ± SE
BMI= Body mass index, WHR= Waist-to-hip ratio, SBP= Systolic blood 
pressure, DBP= Diastolic blood pressure
Table 2. Blood profiles and blood pressure of the subjects during intervention 
period
Variables
Spirulina (n=19) Control (n=18)
P
baseline 12
th week baseline 12
th week
Fasting blood 
glucose (mg/dl)
128.0 ± 3.8
1) 130.3 ± 4.1 127.8 ± 3.5 129.9 ± 7.9 0.216
HbA1C (%)  6.90 ± 0.18  7.07 ± 0.13  6.74 ± 0.13  7.21 ± 0.21 0.503
Insulin (ng/dl)  10.7 ± 0.7  9.01 ± 0.75   9.7 ± 0.9  8.52 ± 0.95 0.495
Total-cholesterol 
(mg/dl)
203.1 ± 8.1 203.8 ± 6.0 186.9 ± 6.4 197.2 ± 10.7 0.740
LDL-cholesterol 
(mg/dl)
129.4 ± 7.5 132.0 ± 5.5 106.9 ± 6.5 112.8 ± 6.6 0.599
HDL-cholesterol 
(mg/dl)
 48.8 ±3.0 50.1.8 ±2.6  52.6 ±3.2  53.1 ± 3.6 0.715
Triglyceride 
(mg/dl)
125.8 ± 14.1 98.5 ± 11.6* 110.7 ± 14.1 128.2 ± 18.1 0.022
LDL/HDL ratio  2.77 ± 0.2  2.73 ± 0.1  1.92 ± 0.1  2.10 ± 0.1 0.353
Atherogenic 
index
 3.38 ± 0.2  3.29 ± 0.2  2.73 ± 0.2  2.92 ± 0.2 0.372
KITT index  2.67 ± 0.1  2.65 ± 0.2  2.61 ± 0.2  2.68 ± 0.2 0.602
SBP (mmHg) 130.7 ± 3.8 129.4 ± 2.7 131.8 ± 4.0 133.4 ± 4.5 0.885
DBP (mmHg)  84.0 ±2.1  79.8 ±2.1  80.1 ±2.5  83.5 ± 2.7 0.021
1) Mean ± SE
P=P r >F by repeated measured ANOVA between spirulina and control group after 
adjusting  for  sex
Asterisk = Significantly different by paired t-test between baseline and 12
th week in 
the  same  intervention  group,  *p<0.05  ,  HbA1C=Hemoglobin  A1C
Table 3. Inflammation and antioxidant status of the subjects during intervention
period
Variables
Spirulina (n=19) Control  (n=18)
P
baseline 12
th week baseline 12
th week
TNF-α (pg/ml) 2.25 ± 0.23
1) 1.71 ± 0.13 2.05 ± 0.50 2.09 ± 0.34 0.447
IL-6 (pg/ml) 1.56 ± 0.08 0.92 ± 0.09 1.10 ± 0.09 1.31 ± 0.28 0.197
Adiponectin 
(μg/ml)
5.52 ± 0.51 6.62 ± 0.68 5.77 ± 0.75 5.69 ± 0.75 0.050
MDA (µM/L) 2.57 ± 0.24 1.85 ± 0.22** 2.02 ± 0.36 1.96 ± 0.24 0.012
1) Mean ± SE
P=P r >F by repeated measured ANOVA between spirulina and control group after 
adjusting  for sex
Asterisk = Significantly different by paired t-test between baseline and 12
th week in 
the  same  intervention  group,  *p<0.05,  **p<0.01
partial correlation coefficients analysis was conducted. Data 
within each group were analyzed by repeated measures analysis 
of variance to establish significant differences in treatment. The 
P value of less than 0.05 was considered statistically significant.
Results
There were no significant differences in baseline characteristics 
between spirulina and control groups such as age, sex and 
diabetic family history, cigarette smoking, alcohol consumption 
(Table 1). Also, no differences were found in anthropometric 
and hematological parameters and dietary intakes.
Blood profiles during the intervention period 
After 12 weeks of intervention, no significant changes were 
observed in the plasma levels of fasting blood glucose (FBG), 
hemoglobin A1c, insulin, total cholesterol, LDL-cholesterol, and 
HDL-cholesterol in either group (Table 2). The atherogenic 
index, KITT,  and blood pressure also were not significantly 
changed for both spirulina and control groups. However, plasma 
level of triglycerides was significantly decreased (from 125.8 
mg/dl to 98.5 mg/dl, p<0.05) after the spirulina intervention. 
Spirulina supplementation showed a significant lowering effect 
on plasma triglyceride level and diastolic blood pressure by 
repeated test for treatment (time x treatment interaction, p<0.05). 
Inflammation and antioxidant status during the Intervention 
period
Changes of plasma levels of inflammatory cytokines and MDA 
during 12 weeks of intervention period are shown in Table 3. 
In spirulina group, the plasma level of malondialdehyde (MDA) 
was significantly decreased (from 2.57 µM/L to 1.85 µM/L, 
p<0.01) and the plasma level of adiponectin showed a tendency 
of an increase (from 5.52 μg/ml to 6.62 μg/ml, p<0.1). No 
differences were observed in the concentrations of TNF-α and 
IL-6 between baseline and end of 12-week intervention period. 
On the other hand, the plasma levels of MDA, adiponectin, TNF-298 Effects of spirulina in type 2 diabetes patients
Table 4. The partial correlation coefficients between blood lipids level at baseline and changes biochemical variables (spirulina group)
Baseline
Changes after 
intervention
Spirulina (n=19) Control  (n=18) 
Triglyceride 
(mg/dl)
Total-cholesterol 
(mg/dl)
LDL-cholesterol 
(mg/dl)
Triglyceride 
(mg/dl)
Total-cholesterol 
(mg/dl)
LDL-cholesterol 
(mg/dl)
Total-cholesterol (mg/dl) -0.238 -0.787** -0.734** -0.051 0.266 0.307
LDL-cholesterol (mg/dl) -0.053 -0.665** -0.689** 0.035 -0.203 -0.376
HDL-cholesterol (mg/dl) 0.116 -0.319 -0.286 -0.024 -0.100 -0.063
Triglyceride (mg/dl) -0.605** 0.072 0.346 -0.519 -0.267 0.030
SBP (mmHg) -0.570* -0.503* -0.314 0.240 0.002 -0.093
DBP (mmHg) -0.501* -0.543* -0.399 -0.051 -0.547 -0.472
TNF-α (pg/ml) -0.108 -0.209 -0.192 0.265 0.203 0.056
IL-6 (pg/ml) -0.099 -0.552* -0.532* -0.008 -0.432 -0.478
Adiponectin (μg/ml) 0.317 0.073 -0.003 -0.399 0.221 0.581
MDA (µM/L) 0.106 -0.382 -0.372 -0.232 0.296 0.449
C o r r e l a t i o n  c o e f f ic i e n t s  a f t e r  a d j u s t i n g  f o r  s e x
*p<0.05,  **p<0.01
α, and IL-6 were not changed after 12 weeks of intervention 
in control group. Repeated test for treatment showed significant 
effects of spirulina supplementation on lowering plasma MDA 
(time × treatment interaction, p<0.05) and on increasing 
adiponectin concentration (time × treatment interaction, p<0.05).
Effect of intervention according to blood lipids level at baseline 
The effect of spirulina supplementation may differ whether the 
subjects have dyslipidemia or not before entering intervention 
study. Therefore, we assessed the correlations between baseline 
blood lipids level and changes of biochemical variables in 
spirulina supplemented subjects (Table 4).
The plasma level of triglyceride at baseline was negatively 
correlated with changes of triglyceride (r=-0.605, p<0.01) and 
systolic blood pressure (r=-0.538, p<0.05). Also, plasma level 
of total cholesterol at baseline was negatively correlated with 
changes of plasma concentrations of total cholesterol (r=-0.787, 
p<0.01), LDL-cholesterol (r=-0.665, p<0.01), and IL-6 (r=-0.552, 
p<0.05), and systolic (r=-0.527, p<0.05) and diastolic blood 
pressure (r=-0.600, p<0.01). Plasma level of LDL-cholesterol at 
baseline showed significant negative correlations with changes 
of total cholesterol (r=-0.734, p<0.01), LDL-cholesterol (r=-0.689, 
p<0.01), diastolic blood pressure (r=-0.516, p<0.05) and IL-6 
(r=-0.532, p<0.05). On the other hand, these trends were not 
found in control subjects. This result indicates that subjects with 
higher lipid concentrations before entering intervention study 
showed higher reduction in lipids, inflammatory cytokine levels, 
and blood pressure by spirulina supplementation. However, changes 
in insulin resistance, adiponectin concentration and antioxidant 
capacity were not affected by initial blood lipid levels of the subjects.
Discussion
Spirulina is reported to be effective for improving blood lipid 
profiles (Torres
  et al., 1998),
  enhancing immune capacity, and 
reducing oxidative stress (Shklar & Schwartz, 1998). Since 
dyslipidemia, oxidative and inflammatory stress are considered 
to be the contributing factors for diabetes, spirulina is the most 
likely candidate as functional food for management of type 2 
diabetes.
Park (2007) reported that spirulina supplementation to healthy 
elderly people with normal fasting blood glucose (FBG) brought 
a significant reduction in mean FBG from 105.1 mg/dl to 100.0 
mg/dl. On the contrary, the spirulina supplementation in patients 
with type 2 diabetes in this study did not result in a reduction 
in the plasma levels of FBG, hemoglobin A1c, and insulin. The 
subjects in this study were type 2 diabetes mellitus (DM) patients 
with FBG>126 mg/dl. Therefore spirulina may not have 
beneficial effect on blood glucose concentration for DM patients.
Many animal and human studies have repeatedly reported the 
lipid-lowering effects of spirulina. Park and Kim (2003)
  reported 
that the plasma levels of triglyceride, total cholesterol, and 
LDL-cholesterol in Korean elderly people were significantly 
decreased after spirulina supplementation for 24 weeks. Also, 
spirulina supplementation to type 2 diabetic patients resulted in 
a significant decrease in plasma concentrations of triglyceride, 
total cholesterol and LDL-cholesterol (Iyer et al., 2001). In an 
animal study, rats fed a 20 % water-soluble fraction of spirulina 
showed a significant reduction in LDL/HDL ratio (Hosoyamada
 
et al., 1991). In our study, no changes were observed in plasma 
concentrations of total cholesterol, LDL-cholesterol, and 
HDL-cholesterol after spirulina intervention, however, a 
significant lowering effect on plasma triglyceride concentration 
was shown. The less profound cholesterol lowering effect in this 
study may be due to baseline lipid concentration of the subjects. 
The cholesterol concentrations of our subjects at baseline were 
in normal ranges, however, the baseline lipid profile of the 
previous study (Park & Kim, 2003) was higher with triglyceride 
of 168.2 mg/dl, and total cholesterol of 231.3 mg/dl, and 
LDL-cholesterol of 154.6 mg/dl. Correlation analysis in this 
study revealed that subjects with higher initial blood levels of 
triglycerides and cholesterol showed a higher reduction in lipid Eun Hee Lee et al. 299
concentration, blood pressure and inflammatory cytokine. 
Therefore, spirulina supplementation was probably more 
effective for lowering total cholesterol in subjects with higher 
blood cholesterol level before intervention. 
Hypotriglyceridemic and blood pressure lowering effects of 
spirulina have been reported. Iwata et al. (1990) postulated that 
the hypotriglyceridemic effect of spirulina might be due to its 
effect on the metabolism of lipoproteins. They reported that rats 
fed a diet containing spirulina showed a significant increase in 
the activity of lipoprotein lipase compared to rats fed a high 
fructose diet. The mechanisms of spirulina on blood pressure are 
not well understood. However, Guan et al. (2007)
  have proposed 
that the high potassium content of spirulina may have a lowering 
effect on blood pressure. 
Oxidative stress may play an important role in the etiology 
of diabetic complications (Giugliano et al., 1996). Kim and Kim 
(2005) reported that healthy elderly subjects received spirulina 
supplementation for 8 weeks showed improved antioxidant status 
as evidenced by increased total antioxidant status and decreased 
thiobarbituric acid reactive substance. In accordance with these 
studies, spirulina supplementation in this study resulted in a 
significant decrease in MDA level from 2.57 µM/L to 1.85 µM/L. 
Also, a significant increase in plasma adiponectin concentration 
was observed in this study after spirulina supplementation. An 
increase in adpionectin concentration with a decrease in oxidative 
stress would play a role in the prevention of DM complication. 
In conclusion, spirulina intervention brought in favorable effect 
on blood lipids, anti-oxidant capacity, and inflammatory response 
in Korean patients with type 2 diabetes. Our results also suggest 
that spirulina is a promising agent as a functional food for the 
management of diabetes. Further studies with larger sample size 
and longer duration are required to ascertain the mechanism of 
spirulina’s actions on lipid profiles, immune variables, and 
antioxidant capacity. 
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